News Wire
Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies
FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101...
Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That...
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Protecting Against Severe Allergic Reactions This Summer
Life-saving medication on the way to U.S. clinics serving low-income and uninsured patients.
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
First clinical study of a bacterial consortium for treating food allergy will initially be studied in patients with history of peanut allergy.
Study: ‘Good’ Bacteria May Prevent – and Reverse – Food Allergy
A study published in Nature Medicine makes a strong case that food allergy is caused by the absence of certain beneficial bacteria in the human gut.
New Cell Discovery Could Potentially Stop Allergies from Developing
The discovery could create a new approach for future allergy treatments.
Illinois State Senator Passes Measure to Protect People with Food Allergies Eating at Restaurants
“I’m hoping this legislation can help people, especially parents, have a sense of ease when going out to eat at a local restaurant.”
Asthma and Allergy Foundation of America Elevates Patient Voice in ICER Review of New...
Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Study Highlights Triggers of Anaphylaxis in Infants, Children
According to the study, triggers for anaphylaxis can differ based on geographical region.
